Why the study?
Strong guidelines are lacking and clinical management remains heterogeneous for older patients on oral anticoagulation therapy who suffer a mild traumatic brain injury.
This review highlights the lack of strong guidelines and the heterogeneity in clinical approaches for managing older patients with mild traumatic brain injury who are on oral anticoagulation therapy.
Absent guidelines sustain heterogeneous OAT management after elderly mTBI; leaves open optimal observation duration and therapy continuation.
The effects of Oral Anticoagulation Therapy (OAT) in older patients who suffered a mild Traumatic Brain Injury (mTBI) are widely debated but still strong guidelines are lacking and clinical approaches and management are sometimes heterogeneous. Different predictors of adverse outcomes were identified in the literature but their use in the decision-making process is unclear. Moreover, there is no consensus on the appropriate length of stay in the Observation Unit nor on the continuation of OAT, even if the diagnosis of life-threatening delayed post-traumatic Intracranial Hemorrhage is rare. The recurrence of a control CT scan is often needless. This review aims to summarize recent scientific literature focusing on patients with mTBI taking OAT and to identify crucial questions on the topic to suggest a best clinical practice.
No takes yet. Share an insight, caveat, or question.
Park et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: